Construction Partners backed as cash-producing buy while RTX and West Pharmaceutical flagged as sells

StockStory··Read original
2▲1 ▼2Impact / 5
Summary · why it matters

StockStory highlights Construction Partners as a cash-producing stock with exciting potential, while advising investors to brush off RTX and West Pharmaceutical Services. Construction Partners, trading at $123.14 per share, posted annual revenue growth of 39.9% over the last two years and earnings per share growth of 46.7%, with its free cash flow margin expanding by 7.4 percentage points over five years. RTX, at $185.63 per share, faces slowing demand with estimated sales growth of 5.9% and a low return on capital of 4.7%. West Pharmaceutical Services, at $336.34 per share, saw unexciting 4.9% annual sales growth and a 5.8 percentage point decline in adjusted operating margin over five years amid rising competition.

Impact on assets 3

Industrials▲ · 1 stocks
Construction Partners Inc
ROAD
▲ PositiveCapitalrelevance

Highlighted as a cash-producing stock with strong revenue and earnings growth, and expanding free cash flow margin.

Defense & Geopolitical Fragmentation▼ · 1 stocks
RTX Corporation
RTX
▼ NegativeDemandrelevance

Faces slowing demand with estimated sales growth of 5.9% and low return on capital.

Biotech & Genomic Medicine▼ · 1 stocks
© 2026 MarketIVNews